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Abstract 
Background: Current risk prediction models in heart failure (HF) including clinical characteristics and biomarkers 
only have moderate predictive value. The aim of this study was to use matrix assisted laser desorption ionisation mass 
spectrometry (MALDI-MS) profiling to determine if a combination of peptides identified with MALDI-MS will better 
predict clinical outcomes of patients with HF.
Methods: A cohort of 100 patients with HF were recruited in the biomarker discovery phase (50 patients who died or 
had a HF hospital admission vs. 50 patients who did not have an event). The peptide extraction from plasma samples 
was performed using reversed phase C18. Then samples were analysed using MALDI-MS. A multiple peptide bio-
marker model was discovered that was able to predict clinical outcomes for patients with HF. Finally, this model was 
validated in an independent cohort with 100 patients with HF.
Results: After normalisation and alignment of all the processed spectra, a total of 11,389 peptides (m/z) were 
detected using MALDI-MS. A multiple biomarker model was developed from 14 plasma peptides that was able to 
predict clinical outcomes in HF patients with an area under the receiver operating characteristic curve (AUC) of 1.000 
(p = 0.0005). This model was validated in an independent cohort with 100 HF patients that yielded an AUC of 0.817 
(p = 0.0005) in the biomarker validation phase. Addition of this model to the BIOSTAT risk prediction model increased 
the predictive probability for clinical outcomes of HF from an AUC value of 0.643 to an AUC of 0.823 (p = 0.0021). 
Moreover, using the prediction model of fourteen peptides and the composite model of the multiple biomarker of 
fourteen peptides with the BIOSTAT risk prediction model achieved a better predictive probability of time-to-event in 
prediction of clinical events in patients with HF (p = 0.0005).
Conclusions: The results obtained in this study suggest that a cluster of plasma peptides using MALDI-MS can reli-
ably predict clinical outcomes in HF that may help enable precision medicine in HF.
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Background
Biomarkers play a major role in the management of 
patients with heart failure (HF) with established roles 
in diagnosis, prognosis, risk stratification and guiding 
therapy. In addition, biomarkers have been shown to be 
useful in understanding the pathophysiology of HF, par-
ticularly in specific phenotypes. Therefore, finding novel 
biomarkers might further improve our understanding 
and management of HF [1].
Matrix assisted laser desorption ionisation mass spec-
trometry (MALDI-MS) has emerged into an important 
proteomic technology, which has been used for analys-
ing plasma proteomic spectra [2–9]. MALDI-MS analy-
sis offers a highly sensitive method for discovery of 
biomarkers directly from complex biological fluids such 
as plasma.
To the best of our knowledge, there has not been any 
study using MALDI-MS technology that enables the 
detection of novel biomarkers predicting clinical out-
comes in patients with HF. The main aim of this study 
was to develop a plasma peptide model that would enable 
better prediction of clinical outcomes in patients with 
HF. In this turn, this may help increase our understand-
ing of the pathophysiology of HF.
Methods
Patient population
Patients were selected from the BIOSTAT-CHF (A sys-
tems BIOlogy Study to TAilored Treatment in Chronic 
Heart Failure) project which was an investigator-driven 
multicentre clinical study [10]. The main aim of this 
project was to identify poor outcomes in HF patients with 
a standard treatment using a systems biology approach 
which includes demographics, biomarkers, genetics and 
proteomics [11, 12]. The BIOSTAT-CHF project was 
conducted according to the declaration of Helsinki which 
was approved by national and local ethics committees. 
All patients provided written informed consent. Partici-
pating subjects who met inclusion and exclusion criteria 
according to the European Society of Cardiology (ESC) 
guideline were collected [13]. In brief, 2516 patients 
were more than 18 years old, presented symptoms of HF 
and had left ventricular ejection fraction (LVEF) ≤ 40% 
and/or B-type natriuretic peptide (BNP) > 400  pg/mL 
or N-terminal pro B-type natriuretic peptide (NT-
proBNP) > 2000 pg/mL who were recruited into the BIO-
STAT-CHF project. At the beginning of the study, blood 
samples were collected for proteomic analysis. Blood was 
drawn by venepuncture that were obtained from supine 
patients after at least 15  min bed rest. Blood was col-
lected in 10 mL EDTA vacutainer tubes, inverted 8 times 
and put on ice immediately. Plasma was obtained after 
centrifugation at 1000g for 15 min at 4 °C, transferred to 
small aliquots and stored at − 80  °C until further analy-
sis. Then the patients received a standard therapy for HF 
which included up-titration with angiotensin converting 
enzyme inhibitors and beta blockers from 0 to 6 months 
to optimise the treatment. Clinical events such as death 
and HF hospitalisation were followed. The plasma sample 
groups were sex and age matched. In the biomarker dis-
covery phase, one group consisted of 50 patients with HF 
(25 male and 25 female) who died or were rehospitalised 
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Table 1 Patient characteristics of biomarker discovery HF patient cohort
Italic values indicate significance of p value (p < 0.05)
BMI body mass index, eGFR estimated glomerular filtration rate, NYHA New York Heart Association
Characteristics HF hospitalisation or death (n = 50) No event (n = 50) p value
Age (years) 76.64 ± 8.14 76.64 ± 8.14 1.000
Male sex, n (%) 25 (50) 25 (50) 1.000
BMI (kg/m2) 30.01 ± 6.17 28.94 ± 6.66 0.471
NYHA class III/IV, n (%) 38 (76) 27 (54) 0.021
Systolic blood pressure (mmHg) 126.38 ± 20.63 130.94 ± 21.12 0.247
Diastolic blood pressure (mmHg) 66.92 ± 11.92 69.22 ± 12.24 0.324
Heart rate (bpm) 75.69 ± 19.91 73.94 ± 18.28 0.848
HF hospitalisation/Death 32/18 0/0
Serum creatinine (µmol/L) 126.88 ± 58.56 107.16 ± 34.27 0.076
eGFR (mL/min−1) 45.76 ± 14.23 51.34 ± 11.19 0.037
Primary aetiology
 Ischemic heart disease 40 (80) 32 (64) 0.118
 Non ischemic heart disease 10 (20) 18 (36) 0.118
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for HF, and they were compared with the group of 50 
HF patients who did not have such an event (Table 1). A 
separate cohort of a hundred HF patient plasma samples 
from the BIOSTAT-CHF project [10] that was employed 
for verification in the biomarker validation phase in this 
study (Table 2). 
Sample preparation
Peptide extraction
Reversed phase  C18  (C18 extra wide pore solid phase 
extraction cartridges) was used to capture peptides in 
plasma samples.  C18 EWP SPE cartridges were primed 
with 1 column volume (3  mL) of methanol and then 
washed with 2 column volumes (6 mL) of 18.2-MΩ-cm 
deionised water before washing with 2 column volumes 
of 0.1% formic acid (FA). 100 μL of each plasma sample 
were mixed with 1  mL of 1% trifluoroacetic acid (TFA) 
and left on ice for 20  min to allow precipitation. Then, 
the sample was centrifuged at 14,000g for 10 min at 4 °C. 
950 µL of the dissolved sample was applied on a  C18 EWP 
SPE cartridge. Each cartridge was washed with 2 column 
volumes of 0.1% formic acid and then 2 column volumes 
of water. Peptides were eluted by adding 1.2 mL elution 
solution of 60% acetonitrile (ACN) + 0.1% formic acid 
(FA) in water and then 1.2 mL of 90% acetonitrile + 0.1% 
formic acid in water. Finally, the eluates were dried by 
using a Speed-Vac (Jouan, Thermo Scientific, USA) for 
2  h and followed by freeze-drying overnight (Edwards, 
Modulyo, BPS, UK). The samples were stored at − 80 °C 
until MALDI-MS analysis.
MALDI spot preparation
The dried samples were reconstituted in 0.1% trifluoro-
acetic acid (TFA). 10 µL of each sample were mixed with 
990  µL of α-CHCA matrix solution (5  mg α-cyano-4-
hydroxycinnamic acid in 1 mL of 50% acetonitrile + 50% 
water with 0.1% trifluoroacetic acid). Then, 1  µL of this 
mixture was spotted in triplicate directly onto a 96 well 
MALDI target plate (Waters Corporation, Manchester, 
UK). The target plates were dried at room temperature 
for 45 min and immediately transferred into the MALDI-
MS for analysis.
Sample analysis
Samples were analysed using a Synapt G2 MALDI 
mass spectrometer (Waters Corporation, Manchester, 
UK) tuned to 10,000 mass resolution (full width at half 
height). The MALDI-MS instrument and mass spectra 
were automatically acquired in positive mode. Peptides 
were detected in a mass range of m/z from 700 to 10,000 
using instrument settings optimised for plasma analysis 
with the following acquisition settings: plate speed: 15, 
laser firing rate: 200, laser energy: 300, mass threshold: 
10. Ionisation was performed with a laser operating at 
a frequency of 1000  Hz. For each MALDI spot, spectra 
were recorded from vertical spot positions.
Data analysis
Raw data files were converted to txt files using MassLynx 
version 4.1 software (Waters Corporation, Manchester, 
UK) before they were imported into Progenesis MALDI 
version 1.4 software (Nonlinear Dynamic, UK). Spectra 
were pre-processed to remove noise and background 
across all spectra: a noise filter size of 5 was applied and 
background subtracted using a top hat filter size of 60. All 
the features in spectra were aligned using a search area 
of 5 before analysis. The data obtained was exported to 
Excel for further analysis.
Table 2 Patient characteristics of the biomarker validation HF patient cohort
Italic values indicate significance of p value (p < 0.05)
BMI body mass index, BNP brain natriuretic peptide, eGFR estimated glomerular filtration rate, NYHA New York Heart Association
Characteristics HF hospitalisation or death (n = 58) No event (n = 42) p value
Age (years) 69.52 ± 12.15 68.86 ± 11.95 0.696
Male sex, n (%) 29 (50.0) 20 (47.6) 0.814
BMI (kg/m2) 27.76 ± 6.20 29.27 ± 5.85 0.125
NYHA class III/IV, n (%) 36 (65.5) 27 (64.3) 0.905
Systolic blood pressure (mmHg) 125.10 ± 25.20 123.52 ± 17.07 0.936
Diastolic blood pressure (mmHg) 72.00 ± 14.41 75.50 ± 11.48 0.054
Heart rate (bpm) 82.53 ± 22.37 83.55 ± 24.52 0.975
BNP (pg/mL) 467.45 ± 433.66 288.49 ± 390.02 0.004
Serum creatinine (µmol/L) 123.72 ± 47.06 101.32 ± 46.09 0.004
eGFR (mL/min−1) 53.74 ± 20.03 67.63 ± 27.72 0.013
Primary aetiology
 Ischaemic heart disease 27 (47.4) 15 (36.6) 0.287
 Non ischaemic heart disease 30 (52.6) 26 (63.4) 0.287
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Statistical analysis
All data for continuous variables are reported as 
mean ± SD. After testing for normal distribution, val-
ues were compared by unpaired Student’s t tests or 
Mann–Whitney U test, as appropriate. All statistical 
tests were performed 2-tailed, and a significance level 
of p value < 0.05 was considered to indicate statistical 
significance. To evaluate test performance of candidate 
biomarkers as predictors for outcomes in patients with 
HF, the area under the receiver operating characteris-
tic curves (AUC) were plotted. The multiple biomarker 
model were built using a logistic regression with candi-
date peptides (m/z) which were entered simultaneously 
in order to improve the predictive probability of out-
comes in patients with HF. The SPSS statistics software 
version 24.0 (Statistical Package for the Social Sciences, 
Chicago, USA) for Windows was employed for all statisti-
cal analyses in this study.
Results
Patient characteristics
Patient characteristics of the biomarker discovery HF 
cohort are described in Table  1. In the biomarker dis-
covery HF patient cohort, the groups were matched 
in age (average age: 76.6 ± 8.1  years old) and gender 
between both HF groups. The age and gender distribu-
tion of both groups of patients with HF was not statis-
tically different (p = 1.000). Therefore, age and gender 
bias was completely excluded.
Patient characteristics of the biomarker validation HF 
patient cohort are displayed in Table 2. Mean age was 
69.5 ± 12.2  years in the patients who died or were re-
hospitalised and 68.9 ± 12.0  years in the patients who 
did not have an event (p = 0.696). In the patients with 
an event, eGFR (mL/min−1) was lower (53.74 ± 20.03 
vs. 67.63 ± 27.72, p = 0.013 and BNP levels (pg/mL) 
were higher (467.45 ± 433.66 vs. 288.49 ± 390.02, 
p = 0.004). All other patient characteristics were not 
significantly different between the two HF groups.
Identification of plasma peptide spectra in patients 
with heart failure
We analysed the plasma peptide profiles of a hundred 
patients with HF in the biomarker discovery cohort and 
a hundred patients with HF in the biomarker validation 
cohort. After normalisation and alignment of all the 
processed spectra, a total of 11,389 peptides (m/z) were 
detected using MALDI-MS combined with  C18 SPE. 
From the 11,389 peptides, expression of 53 peptides 
(m/z) were significantly different in both cohorts in HF 
Table 3 List of  53 peptides (m/z) detected 
in  both  biomarker discovery and  validation HF patient 
cohorts which were significantly different in  expression 
in  the  patients with  HF who responded to  treatment 
as  compared to  the  HF hospitalisation/death at  p 
value < 0.05
m/z Fold change p value
1724.22 0.97 0.034
2279.24 0.94 0.028
2290.24 0.95 0.043
2300.24 0.95 0.029
2410.29 0.95 0.028
2472.34 0.94 0.028
2646.44 1.06 0.019
2691.47 0.93 0.007
2729.47 0.94 0.037
2868.59 1.08 0.018
3113.71 1.07 0.042
5636.08 1.43 0.041
5660.99 1.31 0.049
5855.33 0.82 0.030
5953.32 1.58 0.009
6165.30 1.60 0.036
6279.13 2.26 0.023
6283.58 1.45 0.014
6314.83 1.49 0.031
6446.94 1.24 0.043
6460.55 2.00 0.027
6465.03 2.98 0.004
6515.90 0.38 0.001
6551.62 1.52 0.041
6576.58 1.99 0.004
6576.99 1.55 0.010
6601.97 1.63 0.045
6609.77 1.52 0.047
6722.04 1.61 0.009
6764.13 1.60 0.025
6918.14 1.63 0.028
7061.32 2.99 0.040
7100.13 3.22 0.027
7118.44 1.83 0.037
7121.74 1.69 0.048
7158.59 2.77 0.045
7185.63 2.10 0.028
7213.01 2.17 0.028
7358.59 3.76 0.011
7409.39 0.92 0.002
7463.58 1.74 0.013
7479.14 0.44 0.003
7492.90 0.58 0.027
7526.71 1.60 0.048
7572.41 1.84 0.036
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patients with and without an event at a p value < 0.05 
(Table 3).
Selection of candidate peptide (m/z) biomarkers 
for prediction of clinical outcomes in the biomarker 
discovery phase
To determine if peptides (m/z) could help to discrimi-
nate clinical outcomes between the HF patients with or 
without an event, receiver operating characteristic (ROC) 
curves were generated. Additional file 1: Table S1 shows 
the values of area under the receiver operating character-
istic curves (AUC) for 53 peptides (m/z). The best AUC 
was peptide m/z 6515.90 with AUC of 0.688 at p = 0.001 
(Asymptotic 95% confidence interval [CI], 0.583—0.793) 
that is presented in Fig. 1.
However, no individual peptide (m/z) was an excellent 
classifier for prediction of clinical outcomes in patients 
with HF. Therefore, the development of a multiple pep-
tide biomarker approach would be useful to provide 
more pathophysiological information about patients with 
HF and able to predict clinical outcomes. We developed 
a multiple biomarker model with fourteen peptides (m/z 
2646.44, 2729.47, 3113.71, 5636.08, 5855.33, 5953.32, 
6314.83, 6465.03, 6515.90, 7061.32, 7358.59, 7492.90, 
7582.00 and 7929.78) by using a logistic regression in 
which all these peptides were entered simultaneously 
(Additional file  1: Table  S1 and Additional file  2: Figure 
S1). The AUC value in the multiple biomarker model of 
fourteen peptides showed an excellent improvement 
in the performance of predictive probability for clini-
cal outcomes in patients with HF with an AUC of 1.000 
(Asymptotic 95% CI, 1.000–1.000) at p = 0.0005. The pre-
diction capability of this model achieved 100% sensitivity 
and 100% specificity (Fig. 1). There was a very good sepa-
ration between the HF patients who responded to treat-
ment and HF hospitalisation or death which is displayed 
in a scatter 3D plot of fourteen peptide model (Additional 
file 3: Figure S2).
Validation of candidate peptide (m/z) biomarkers 
for prediction of clinical outcomes in the biomarker 
validation phase
To confirm the result achieved in the biomarker discov-
ery phase, the multiple biomarker model with a combina-
tion of fourteen peptides discovered from the biomarker 
discovery HF patient cohort was tested in the biomarker 
validation HF patient cohort with another hundred 
patients with HF. The AUC value of this multiple bio-
marker model with the fourteen peptides yielded an AUC 
of 0.817 at the p value of 0.0005 (Asymptotic 95% CI 
0.734–0.900) that is shown in Fig. 2 and Table 4.
The added value of the multiple peptide biomarker model 
on top of the BIOSTAT risk prediction model
Recently, we developed a risk prediction model for 
patients with HF from the BIOSTAT-CHF cohort [14] 
which risk scores can be calculated using the online cal-
culator available at: http://www.biost at-chf.eu (includ-
ing age, HF hospitalisation last year, peripheral oedema, 
Table 3 (continued)
m/z Fold change p value
7582.00 5.29 0.016
7600.74 2.25 0.018
7634.93 1.81 0.013
7649.22 3.10 0.033
7889.48 1.66 0.033
7914.92 2.78 0.005
7928.13 0.31 0.006
7929.78 3.25 0.028
Fig. 1 Receiver operating characteristic (ROC) curve of peptide m/z 
6515.90 and the multiple biomarker model of fourteen peptides 
for prediction of clinical outcomes in the biomarker discovery HF 
patient cohort. The blue curve displays the best AUC with a single 
biomarker was peptide m/z 6515.90 with AUC of 0.688 (Asymptotic 
95% confidence interval [CI], 0.583–0.793, p = 0.001) in discriminating 
the HF patients who respond to treatment from HF hospitalisation/
death. The green curve shows a multiple biomarker model with 
fourteen peptides (m/z 2646.44, 2729.47, 3113.71, 5636.08, 5855.33, 
5953.32, 6314.83, 6465.03, 6515.90, 7061.32, 7358.59, 7492.90, 7582.00 
and 7929.78) with an excellent improvement in the performance of 
predictive probability for clinical outcomes in patients with HF with 
an AUC of 1.000 (Asymptotic 95% CI, 1.000–1.000, p = 0.0005)
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systolic blood pressure, NT-proBNP, haemoglobin, high-
density lipoprotein, serum sodium and beta-blocker use 
at baseline). Using the BIOSTAT risk prediction model 
generated an AUC value of 0.643 (Asymptotic 95% CI 
0.530–0.757) with p value of 0.015 (Fig.  2 and Table  4). 
Interestingly, the added value of the prediction model of 
fourteen peptides on top of the BIOSTAT risk predic-
tion model achieved an AUC of 0.823 (Asymptotic 95% 
CI 0.743–0.904, p = 0.0005) that is displayed in Fig. 2 and 
Table  4. The increase in the AUC value of the compos-
ite model of the BIOSTAT risk prediction model with the 
multiple peptide model as compared to the BIOSTAT risk 
prediction model had a statistically significant p value of 
0.0021. In addition, using the prediction model of four-
teen peptides and the composite model of the multiple 
biomarker of fourteen peptides with the BIOSTAT risk 
prediction model gave a better predictive probability of 
time-to-event in prediction of clinical events in patients 
with HF (p = 0.0005, Additional file 4: Figure S3).
Discussion
There is no single effective parameter to predict clinical 
outcomes in patients with HF. Therefore, several mod-
els have been applied to predict mortality and HF hos-
pitalization in patients with HF. In a meta-analysis, the 
mean c-statistics of all of these models to predict mortal-
ity and/or HF admission was only 0.63 [15]. Recently, we 
developed a risk prediction model from the BIOSTAT-
CHF cohorts, which yielded a c-statistics of 0.71 to pre-
dict death or HF admission [14]. Therefore, a method to 
enable clinicians to better predict clinical outcomes in 
HF would be important and useful for improving prog-
nostication and in stratifying patients with HF. Using 
the MALDI-MS technique for proteomic analysis is one 
of the most promising approaches for the discovery and 
identification of peptides and proteins in many diseases. 
Based on this technology, some biomarkers of several 
diseases have been discovered, particularly in cancer 
[2–9]. Thus we sought to see if we could devise a strat-
egy to combine MALDI-MS and  C18 SPE technique and 
employ statistical tools to establishing a model that could 
discriminate between HF patients who respond to treat-
ment and HF hospitalisation or death.
In this study, a total of 11,389 peptides (m/z) were 
detected using MALDI-MS combined with  C18 SPE in 
both biomarker discovery and validation HF patient 
cohort. Moreover, 53 peptides showed a significantly 
different expression between patients who died or had a 
Fig. 2 Receiver operating characteristic (ROC) curve of the multiple 
biomarker model with fourteen peptides for prediction of clinical 
outcomes of HF in comparison with the BIOSTAT risk prediction 
model and the added value of the prediction model of fourteen 
peptides on top of the BIOSTAT risk prediction model. The red curve 
presents the BIOSTAT risk prediction model with an AUC value of 
0.643 (Asymptotic 95% CI 0.530–0.757, p = 0.015) that risk scores 
were calculated using the online calculator available at: http://
www.biost at-chf.eu (including age, HF hospitalisation last year, 
peripheral oedema, systolic blood pressure, NT-proBNP, haemoglobin, 
high-density lipoprotein, serum sodium and beta-blocker use at 
baseline). The green curve describes the multiple biomarker model 
with the fourteen peptides with an AUC of 0.817 (Asymptotic 95% 
CI 0.734–0.900, p = 0.0005). The blue curve displays the prediction 
model of fourteen peptides on top of the BIOSTAT risk prediction 
model with an AUC of 0.823 (Asymptotic 95% CI 0.743–0.904, 
p = 0.0005)
Table 4 AUC values of  the  multiple biomarker model of  fourteen peptides for  prediction of  clinical outcomes 
in the biomarker validation HF patient cohort in comparison with the BIOSTAT risk prediction model and the added value 
of the prediction model of fourteen peptides on top of the BIOSTAT risk prediction model
m/z AUC Standard error p value Asymptotic 95% confidence interval
Lower bound Upper bound
BIOSTAT risk prediction model 0.643 0.058 0.015 0.530 0.757
Prediction model of 14 peptides 0.817 0.042 0.0005 0.734 0.900
Prediction model of 14 peptides tested on top of 
the BIOSTAT risk prediction model
0.823 0.041 0.0005 0.743 0.904
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HF admission and those who did not have such an event. 
These results demonstrated that MALDI-MS profiling 
could be used to discriminate between HF patients with 
and without clinical events. These peptides correspond 
to small proteins or fragments of proteins in plasma that 
might have important roles in the pathogenesis of the HF.
The change in expression of peptides reflects changes 
in plasma which could potentially be due to pathophysi-
ological processes in HF. Thus, it is unlikely that there 
would be a single peptide which could be able to identify 
clinical outcomes in patients with HF. With a single bio-
marker, peptide m/z 6515.90 gave the best AUC value of 
0.688 (p = 0.001) in discriminating the HF patients who 
respond to treatment from HF patients with death/rehos-
pitalisation (Fig. 1). However, due to the heterogeneity of 
clinical populations (age, sex, ethnicity and comorbidity) 
an ideal single biomarker may not exist for each disease 
[16]. Some reports have demonstrated that a panel of 
multiple potential biomarkers in a specific model could 
improve precision and be more robust [17–19]. There-
fore, we developed a multiple biomarker model with a 
cluster of peptides (m/z) that would provide better pre-
diction of clinical outcomes for patients with HF. The 
performance of this multiple biomarker model was much 
better as compared to each single peptide biomarker 
for prediction of clinical outcomes in patients with 
HF (Fig.  1 and Table  4). The multiple biomarker model 
with fourteen peptides (m/z 2646.44, 2729.47, 3113.71, 
5636.08, 5855.33, 5953.32, 6314.83, 6465.03, 6515.90, 
7061.32, 7358.59, 7492.90, 7582.00 and 7929.78) gave an 
excellent area under the ROC curve of 1.000, p = 0.0005 
(Fig.  1). This discrimination value was maintained with 
an AUC of 0.817 (p = 0.0005) in the biomarker valida-
tion HF patient cohort (Fig. 2 and Table 4). In addition, 
this multiple biomarker model added a statistically sig-
nificant increase in the predictive probability for clinical 
outcomes in patients with HF (AUC = 0.823, p = 0.0005) 
when it was tested on top of the BIOSTAT risk predic-
tion model or as compared to the BIOSTAT risk pre-
diction model alone (AUC = 0.643), respectively (Fig.  2 
and Table  4). The increase in the AUC value between 
the BIOSTAT risk prediction model and the composite 
model of the BIOSTAT risk prediction model with the 
multiple peptide model was statistically significant.
Whilst some of these peptides could be derived from 
just one protein, it is likely that these fourteen peptides 
belong to several proteins. Identification of the peptides 
could provide more information about the pathogenesis 
in patients with HF in order to guide therapy. The multi-
ple biomarker model of fourteen peptides may be useful 
if it could be applied for clinical practice. The prediction 
of clinical outcomes in patients with HF would be signifi-
cantly improved using this multiple peptide biomarker 
model. Furthermore, the findings in this study demon-
strated that there is a lot of predictive information in the 
proteomics which are not represented by the clinical fac-
tors and well-known biomarkers in the BIOSTAT risk 
prediction model. Therefore, proteomics mechanisms 
may improve our insight into the pathophysiological 
processes in HF that opens new perspectives for transla-
tional research in HF.
Fig. 3 (Central illustration): Workflow of the biomarker discovery and validation phase for prediction of clinical outcomes in patients with heart 
failure using MALDI-MS
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This is the first study using MALDI-MS profiling in 
order to predict clinical outcomes of patients with HF. 
The results obtained in this study demonstrated that 
MALDI-MS combined with  C18 SPE technique is a good 
approach for discovery of potential biomarkers in plasma 
of patients with HF (Fig.  3: Central Illustration). This 
method also has the potential to provide insight into the 
pathophysiological processes in HF. MALDI is already 
established in some microbiology sections of clinical lab-
oratories and consequently the expertise is already pre-
sent to incorporate this kind of testing in the future [20, 
21]. In addition, identification of clinical outcomes in HF 
that allow measurement of the disease on a peptide level. 
Therefore, this may result in their use in prognostication 
and selection of appropriate treatment in order to tailor 
therapeutics in HF [22].
A limitation of this study is that the mass spectrometer 
in our laboratory for MALDI technique only provides 
the m/z peptide peaks and their intensities to generate 
a profile for prediction of clinical outcomes in patients 
with HF, rather than identifying the underlying peptides 
or proteins. Another limitation of this study is that BIO-
STAT-CHF project was exclusively Caucasian due to the 
study design. Therefore, the results of this study may only 
apply to patients of Caucasian ethnicity.
Conclusions
In conclusion, to the best of our knowledge, this is the 
first study which discovered potential peptide biomarkers 
and a multiple peptide biomarker model for predicting 
clinical outcomes in patients with HF by using MALDI-
MS combined with  C18 SPE. The multiple peptide model 
in this study provided significant additional predictive 
information to the existing BIOSTAT risk prediction 
model. Further identification of these peptides may have 
important therapeutic implications for patients with HF 
in order to improve poor outcomes.
Additional files
Additional file 1: Table S1. AUC values of 53 peptides (m/z) and the 
multiple biomarker model of fourteen peptides for prediction of clinical 
outcomes in the biomarker discovery HF patient cohort.
Additional file 2: Figure S1. Representative mass spectra of fourteen 
peptides (m/z) in the multiple biomarker model for prediction of clinical 
outcomes in patients with HF. There are m/z 2646.44, 2729.47, 3113.71, 
5636.08, 5855.33, 5953.32, 6314.83, 6465.03, 6515.90, 7061.32, 7358.59, 
7492.90, 7582.00 and 7929.78.
Additional file 3: Figure S2. Scatter 3D plot of fourteen peptides for 
predicting clinical outcomes in the biomarker discovery HF patient cohort. 
Each data sphere in the 3D plot corresponds to a patient with X-axis for 
treatment response, peptide (m/z) peak for the Y-axis, and Z-axis for the 
patient samples. This plot shows a very good separation between the HF 
patients who responded to treatment (green sphere) and HF hospitalisa-
tion or death (blue sphere).
Additional file 4: Figure S3. Predictive probability of time-to-event in 
patients with HF using the BIOSTAT prediction model, the prediction 
model of fourteen peptides and the combination model of prediction 
model of fourteen peptides and the BIOSTAT risk prediction.
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